TORNTPHARM.NS - Torrent Pharmaceuticals Limited

NSE - NSE Real Time Price. Currency in INR
-19.75 (-1.23%)
At close: 3:30PM IST
Stock chart is not supported by your current browser
Previous Close1,605.45
Bid0.00 x 0
Ask0.00 x 0
Day's Range1,575.05 - 1,628.20
52 Week Range1,404.55 - 1,962.00
Avg. Volume246,185
Market Cap268.337B
Beta (3Y Monthly)1.08
PE Ratio (TTM)61.51
EPS (TTM)25.78
Earnings DateN/A
Forward Dividend & Yield17.00 (1.10%)
Ex-Dividend Date2019-06-13
1y Target EstN/A
  • 3 things your family needs to know about travel and taxes ahead of the weekend
    Yahoo Finance4 months ago

    3 things your family needs to know about travel and taxes ahead of the weekend

    A weekly round-up of the consumer news you need to know for the weekend, including Richard Branson slamming U.S. paid vacation policies, taxes on par, and asbestos found in Claire's make-up.

  • Reuters10 months ago

    FDA halts imports from China's Huahai after heart drug recall

    SHANGHAI/NEW YORK, Sept 28 (Reuters) - The U.S. Food and Drug Administration said on Friday it will no longer allow imports of drug ingredients or medicines made with ingredients produced by China's Zhejiang Huahai Pharmaceuticals, after a recall of one of its drugs that contained a probable carcinogen. The Chinese bulk manufacturer of the high blood pressure treatment valsartan recalled the product from consumers in the United States in July because an impurity linked to cancer had been detected. European authorities also said on Friday that they had found that Huahai did not comply with good manufacturing practices and that the company's factory in Linhai, China, was no longer authorized to produce valsartan.

  • Reuters10 months ago

    Global health regulators find second toxin in common heart drug

    FRANKFURT/BENGALURU, Sept 14 (Reuters) - European and North American regulators have found a second toxin that may cause cancer in humans in a commonly used blood pressure drug made by Chinese firm Zhejiang Huahai Pharmaceutical Co Ltd. Health regulators in the European Union, United States and Canada had already recalled drugs made with the company's active pharmaceutical ingredient valsartan after finding traces of the chemical N-nitrosodimethylamine (NDMA), considered a potential human carcinogen, in the medicine. On Thursday, the European Medicines Agency (EMA) said a different chemical, N-nitrosodiethylamine (NDEA), had been detected in products produced before 2012.